Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Identification of biomarkers indicative of Respiratory Syncytial Virus (RSV) vaccine-induced immune responses
FY 2014-15
Summary
Respiratory Syncytial Virus (RSV) is the most common cause of bronchitis. The infection is associated with 25% of all hospital admissions of lower respiratory tract disease amongst infants younger than one year. It is also increasingly recognized as an important pathogen in immunocompromised patients and seniors, with infection rates reaching the level of the seasonal flu. At this time, no vaccine is available for the prevention of RSV-induced diseases and antiviral drugs are of questionable benefit. While various candidate RSV vaccines have been clinically investigated, none have been licensed thus far. The development of RSV vaccine has had a significant setback in the past, which substantially hindered new RSV vaccine development. Specifically, an inactivated RSV vaccine was found to be poorly protective and to unexpectedly enhance subsequent RSV infections, with approximately 80% of vaccinated people requiring hospitalization. Therefore, there is an urgent need to better understand RSV vaccinology, particularly biomarkers which are indicative of protection versus adverse reaction. I will use systems biology to identify such biomarkers, which could be of use to evaluate new RSV vaccines. I will conduct animal studies using cotton rats as experimental models since cotton rats are the only reliable models to study RSV vaccine protection effects.
RSV infection is a serious public health issue. A safe and effective RSV vaccine would be the best means of preventing widespread RSV outbreaks. The biggest knowledge gap preventing the licensure of such a vaccine is the lack of understanding of RSV-induced immunopathology. The proposed research will identify meaningful biomarkers, which could be of use in RSV vaccine development.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
331492
Name
Muralidharan Abenaya
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification of biomarkers indicative of Respiratory Syncytial Virus (RSV) vaccine-induced immune responses
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Immunopathology; Lipidomics; Proteomics; Respiratory Syncytial Virus; Vaccine Development
Abstract
Respiratory Syncytial Virus (RSV) is the most common cause of bronchitis. The infection is associated with 25% of all hospital admissions of lower respiratory tract disease amongst infants younger than one year. It is also increasingly recognized as an important pathogen in immunocompromised patients and seniors, with infection rates reaching the level of the seasonal flu. At this time, no vaccine is available for the prevention of RSV-induced diseases and antiviral drugs are of questionable benefit. While various candidate RSV vaccines have been clinically investigated, none have been licensed thus far. The development of RSV vaccine has had a significant setback in the past, which substantially hindered new RSV vaccine development. Specifically, an inactivated RSV vaccine was found to be poorly protective and to unexpectedly enhance subsequent RSV infections, with approximately 80% of vaccinated people requiring hospitalization. Therefore, there is an urgent need to better understand RSV vaccinology, particularly biomarkers which are indicative of protection versus adverse reaction. I will use systems biology to identify such biomarkers, which could be of use to evaluate new RSV vaccines. I will conduct animal studies using cotton rats as experimental models since cotton rats are the only reliable models to study RSV vaccine protection effects.
RSV infection is a serious public health issue. A safe and effective RSV vaccine would be the best means of preventing widespread RSV outbreaks. The biggest knowledge gap preventing the licensure of such a vaccine is the lack of understanding of RSV-induced immunopathology. The proposed research will identify meaningful biomarkers, which could be of use in RSV vaccine development.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Muralidharan, Abenaya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~